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Hydrogels can potentially prolong the release of a therapeutic protein, especially to 
treat blinding conditions. One challenge is to ensure the protein and hydrogel are 
intimately mixed by better protein entanglement within the hydrogel. N-
isopropylacrylamide (NIPAAM) gels were optimised with PEG-diacrylate (PEGDA) 
crosslinker in the presence of either bevacizumab or PEG conjugated ranibizumab 
(PEG10-Fabrani). The release profiles of the hydrogels were evaluated using an 
outflow model of the eye, which has been previously validated for human clearance 
of proteins. Release kinetics of in situ loaded bevacizumab-NIPAAM gels displayed a 
prolonged bimodal release profile in PBS compared to bevacizumab loaded into a 
preformed NIPAAM gel. Bevacizumab release in simulated vitreous from in situ 
loaded gels was similar to bevacizumab control indicating that diffusion through the 
vitreous rather than from the gel was rate limiting. Ranibizumab was site-specifically 
PEGylated by disulfide rebridging conjugation. Prolonged and continuous release 
was observed with the in situ loaded PEG10-Fabrani-NIPAAM gels compared to 
PEG10-Fabrani injection (control). Compared to an unmodified protein, there is better 
mixing due to PEG entanglement and compatibility of PEG10-Fabrani within the 
NIPAAM-PEDGA hydrogel. These encouraging results suggest that the extended 
release of PEGylated proteins in the vitreous can be achieved using injectable 
hydrogels.   
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1.  Introduction 
Hydrogels are frequently considered as materials that can be used to prolong the 
duration of action of therapeutic proteins.[1] A limitation of crosslinked hydrogels is it 
is not possible to mix a large molecule (such as an antibody) efficiently within a pre-
existing hydrogel.  One strategy to address this ‘mixing problem’ is to form the 
hydrogel in the presence of the protein in solution.  The high water content within the 
hydrogel is thought to be important for maintaining protein stability, but the high water 
content often results in burst release profiles for water soluble actives, such as 
proteins.[2] In situ collapsing hydrogels[3-4] have been used to avoid a 'burst' release 
phase and to prolong the overall drug release profile.[5-7] 
Therapeutic antibodies are increasingly being used to treat blinding 
conditions.  Antibody based medicines that bind to vascular endothelial growth factor 
(VEGF) are administered by intravitreal (IVT) injection to treat wet age-related 
macular degeneration (AMD), which is the main cause of blindness in the elderly 
population.  While IVT injections are the best way to administer a reproducible dose 
of an antibody to the back of the eye,[8] clinical practice is hampered by the need for  
IVT injections of these medicines every 1-2 months.  To better treat chronic blinding 
conditions, there is a need to develop ocular formulations that could maintain a 
therapeutic dose of a medicine in the vitreous cavity for longer periods of time.[9-13]   
To this end, IVT implants for the sustained delivery of low molecular weight 
poorly soluble actives, e.g. corticosteroids have been clinically approved.[14-15] The 
formulation of analogous IVT implants utilising a protein therapeutic is limited due to 
protein aggregation.[16-17]  Particulate associated formulations (e.g. nano- and 
microspheres) are widely described[18] and while there has been much research to 
develop these formulations for intraocular use[19], most clinically registered products 
are for non-ophthalmic indications and are derived from low molecular weight 
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molecules and peptides such as Exenatide®, Sandostatin®, Vivitrol® and Risperdal
 
Consta®.[20-23]  
Particulate formulations often use polymers (e.g. poly(lactic-co-glycolic acid) 
(PLGA)[24]) that must be processed using organic solvents and/or require 
emulsification processes.  Scale up and sterilisation processes are limited because 
of protein stability.[1, 25-26]  However particulate associated formulations of proteins for 
IVT injections have been described.[9, 27]  Particles which are prone to aggregation or 
larger than 300 nm in the vitreous can scatter light to interfere with vision.[28]  Particle 
migration to the front of the eye[9, 27] results in release of drug that simply clears from 
the eye with aqueous outflow.  An additional risk is particulates blocking the aqueous 
outflow.  
To avoid issues with particulates and regular IVT injection, a surgically 
implanted port delivery system for ranibizumab is currently in clinical trials.[29]  
Ranibizumab is an antibody Fab that is clinically approved to treat AMD and is 
typically administered monthly.  The implant port delivery system would be refilled 
with ranibizumab once every four months.  To avoid potential implantation issues 
(e.g. foreign body response, ocular infection) and the limitations of free 
particulates,[30] hydrogels[17, 31-32] including collapsible gel systems[5] have emerged as 
potential platforms for extending the duration of action of therapeutic proteins.  
Responsive hydrogels that collapse in physiological conditions can entrap a 
therapeutic protein,[33-35] so that if protein loaded hydrogel can be injected into the 
posterior cavity of the eye, the hydrogel could then collapse to then act as a depot to 
prolong the release of the protein.  Design of a collapsible hydrogel should account 
for the presence of less water to avoid protein degradation.  Thermoresponsive 
polymers derived from N-isopropylacylamide (NIPAAM) have been utilised in many 
drug delivery and tissue engineering studies.[36]  NIPAAM has been shown to display 
no retinal toxicity in vivo[37] although formulations derived entirely from NIPAAM are 
not expected to be resorbable.  When NIPAAM is prepared in the presence of a 
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small amount of a di-acrylate crosslinker (e.g. polyethylene (glycol) diacrylate 
(PEGDA)), a NIPAAM hydrogel will form.  To ensure that there is good protein 
encapsulation during hydrogel formation, polymerisation bond forming reactions must 
be orthongonal to avoid reaction with the protein.  For example thiol derived 
crosslinks[17] that could leave residual thiol would be expected to undergo disulfide 
scrambling reactions with an entrapped therapeutic protein.  
To address the protein mixing challenge in hydrogels, we prepared NIPAAM 
hydrogels in the presence of bevacizumab and PEGylated ranibizumab to compare 
the release profiles of the proteins from the collapsed NIPAAM hydrogel. The in vitro 
release profiles of these protein loaded NIPAAM hydrogels were studied in an in vitro 
outflow model called the PK-Eye.[38-40] This model has been shown to estimate 
human clearance times of protein therapeutics from the back of the eye. The PK-Eye 
reduces animal use during preclinical development and avoids the intractable 
problems associated with the development of anti-drug antibodies (ADAs). 
2.  Results and Discussion 
2.1  Bevacizumab loaded NIPAAM hydrogel preparation and characterisation 
The relative molar amounts of PEGDA to NIPAAM ranged from 1.8 to 9.1% to 
evaluate crosslink densities to prepare a hydrogel that could potentially be injected 
prior to its collapse. The injectability of the gels were determined qualitatively by 
ensuring they could pass with little resistance through a 23 G needle for these 
studies.  Gels prepared using 4 and 8 μL (6.4 and 13 μM respectively) of PEGDA 
were easily injectable.  Higher amounts of PEGDA (i.e. 12 to 20 μL) crosslinker 
produced gels that were less easily injectable. In a similar study with NIPAAM and 
PEGDA, ~8 μM of PEGDA was found to be an optimal crosslinker concentration to 
ensure ease of injection through slightly smaller gauge needles (<27-30 G).[41]  
The NIPAAM hydrogels were characterised to further aid the selection of the 
crosslink density to be used to evaluate bevacizumab entrapment (Figure 1A-C, left 
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column). DSC analysis indicated that the VPTT varied only slightly in the range 34.3 
± 0.2 to 36.2 ± 0.2°C for PEGDA amounts from 4 to 15 μL (Figure 1A, left column). 
These VPTT values were only slightly higher than other NIPAAM-PEGDA hydrogels 
(33°C) that have been reported. As expected the swelling ratio (SR) decreased with 
increased levels of the PEGDA crosslinker at 25°C (Figure 1B, left column). After gel 
collapse at 37°C, the overall SR decreased at low relative crosslink density (Figure 
1B, left column) where collapse appeared more complete. The percentage water 
retention (WR%) after gel collapse (37˚C) indicated that more water was expelled 
after gel collapse at low relative crosslink density (Figure 1C, left column), which was 
consistent with the SR.  
The amount of water that is associated within a hydrogel can be influenced by 
polymer composition, crosslink density and protein loading. Decreased hydrogel 
swelling occurs with an increase in crosslink density (Figure 1C, left column). 
Although many diacrylate crosslinkers are available, PEGDA was selected because it 
is known as a pore-forming agent when used for hydrogel preparation.[34] The 
hydration and the steric shielding properties of PEG may be important to form a more 
porous hydrogel structure[42] and to eventually encourage PEG entanglement with a 
PEGylated protein. PEGDA (Mn 700) was selected because it was thought the 
molecular weight was large enough to display PEG steric shielding needed to 
produce a porous hydrogel. PEGDA (Mn 700) was also thought to be a low enough 
molecular weight to maintain a physiologically relevant NIPAAM LCST. Increased 
PEG molecular weights give hydrogels a higher temperature transition point.[42]   
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Figure 1. Characterisation of unloaded (control, left column) and bevacizumab (right column) 
loaded NIPAAM hydrogels. (A) Volume phase transition temperature (VPTT) with DSC at 
2°C/min from 20 to 50°C; (B) swelling ratio (SR) measured at 25, 37 and 48°C and (C) water 
retention percentage (WR%) at 37°C. All data presented was done in triplicate (n=3) and 
presented as its mean and standard deviation (± STD). 
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2.2  Bevacizumab dose determination 
Bevacizumab is not licensed for IVT injection and has been used as a substitute for 
ranibizumab, which is a Fab that also binds to VEGF and is clinically registered to 
treat AMD.[43-44] The ophthalmic use of bevacizumab has been driven by cost 
because ranibizumab is considerably more expensive per dose. The clinical IVT 
dose of bevacizumab is 1.25 mg which is the amount obtained from 50 μL of 
bevacizumab (25 mg/mL) that is formulated for use in oncology.[45]  
Prior to loading bevacizumab into the NIPAAM gel, three doses of 
bevacizumab (Figure 2) were evaluated using the PK-Eye to determine clearance 
times.  The PK-Eye is a two compartment, aqueous outflow model scaled to the eye 
that has been shown to estimate the human clearance times of therapeutic proteins 
from the back of the eye.[39]. Novel formulations of protein therapeutics and long 
acting implants can be optimised and in vitro in vivo correlations (IVIVCs) 
elucidated.[38, 40] In vitro models are widely used in preclinical development designed 
to determine intraocular release kinetics of therapeutic proteins. Aqueous outflow 
(2.0-2.5 μL/min) is the main cause of mass trasfer within the eye.[46-50] In research, 
little has been reported to develop an in vitro model that accounts for the aqueous 
flow to estimate clearance times for molecules that exit the eye predominantly via the 
anterior route such as therapeutic proteins. Early preclinical development times can 
be accelerated until an optimised formulation is obtained. This avoids the 
unnecessary use of animals, which generally (i) carry the risk of developing ADAs[51-
55] and (ii) do not account for many differences anatomical differences that exist 
between animal and human eyes.[56-57] A significant amount of effort is necessary to 
obtain protein stability and functional data from animal models. Protein stability may 
be lost in long acting formulations designed for the vitreous cavity. One potential 
advantage of the PK-Eye is the ease to evaluate protein properties such as stability 
and functionality. Animals can quickly develop ADAs, which is an intractable problem 
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that negatively impacts the preclinical development of long lasting dosage forms or 
devices for ocular use (Figures S1-S3).  
The fitting model in Origin showed a first order release kinetics with a mono-
exponential decay. A 1.25 mg dose of bevacizumab displayed a k value of 0.068 ± 
0.0004 days-1 and an estimated outflow clearance half-life (t1/2) of 10.1 ± 0.7 days 
using simulated vitreous in the PK-Eye model (Figure 2A), which is comparable to 
what is observed in humans (6.7-10.0 days).[58-61] The bevacizumab dose was 
increased to 2.5 and 5.0 mg and clearance t1/2 times of 15.4 ± 0.7 and 18.3 ± 1.1 
days were observed respectively using simulated vitreous in the PK-Eye (Figure 2B). 
An ocular hydrogel formulation of a therapeutic protein requires the protein to 
first diffuse from the gel followed then diffuse from the vitreous cavity.  In an animal 
model, the prolonged exposure to a protein therapeutic would be expected to 
generate ADAs when using a human derived protein. Understanding the effects of 
the hydrogel to optimise a formulation can be more efficiently studied in a relevant 
non-animal model, such as the one used in this study. Using this strategy is more 
efficient for developing other dosage forms (e.g. oral)..  
Considering the amount of bevacizumab to incorporate into a NIPAAM 
hydrogel was important. Adding more mass of bevacizumab (or any drug) into a final 
dosage form is a strategy that can increase the number of clearance t1/2s before a 
sub-therapeutic concentration is reached. This strategy exploits a therapeutic tail that 
is possible for potent molecules. For example, aflibercept is an antibody fusion 
protein that also binds to VEGF for the treatment of AMD. Aflibercept is administered 
by IVT injection about every 2 months.[62] More aflibercept on a molar basis is in the 
IVT injection volume than the other antibody based drugs that are dosed once 
monthly to treat AMD (i.e. bevacizumab and ranibizumab).  
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Figure 2. In vitro release profiles of different bevacizumab doses at 37°C to determine the 
bevacizumab pNIPAAM loading. (A) Clinical dose of bevacizumab (1.25 mg) in simulated 
vitreous.  Larger doses (2.5 and 5.0 mg) in (B) simulated vitreous and (C) PBS, pH 7.4. All 
data obtained by HPLC (280 nm) in triplicate (n=3) and presented as its mean and standard 
deviation (± STD). 
Although aflibercept is dosed less frequently than either ranibizumab or 
bevacizumab, this is not because there is any significant increase in the vitreal t1/2 of 
aflibercept compared to either ranibizumab or bevacizumab. A strategy based simply 
on having more bevacizumab in a 50 μL IVT injection volume would not be expected 
to dramatically increase the duration of action of bevacizumab to more than 2 
months, but loading a larger dose of bevacizumab into a gel may offer the 













































































































































opportunity to increase the duration of action of an injectable gel-based form of 
bevacizumab. 
Dose escalation was also conducted using PBS in the vitreous cavity of the 
PK-Eye. PBS was then used instead of simulated vitreous in the posterior cavity of 
the PK-Eye to compare and to observe relative clearance t1/2s more quickly. The 2.5 
and 5.0 mg bevacizumab doses displayed a t1/2 of 2.4 ± 0.8 and 3.5 ± 0.7 days 
respectively (Figure 2C). The percentage of the protein that cleared from the 
posterior cavity of the PK-Eye using PBS by day 9 was 95.1 ± 3.1 and 83.0 ± 7.9 % 
for the 2.5 and 5.0 mg doses respectively. For comparison, a t1/2 of 1.2 ± 0.1 days 
and a protein release of 93.6 ± 7.6% was observed for the clearance of the clinical 
dose (1.25 mg) of bevacizumab with PBS in the PK-Eye.[39]  
The same strategy to add as more drug to a formulation is also seen with 
subcutaneous drugs (SC), for example, the initial formulation of glatiramer was a 
20.0 mg dose for daily SC administration. The next generation formulation of 
glatiramer was 40.0 mg dose in the same 1.0 mL volume for 3 times weekly 
administration. With more glatiramer in the 40.0 mg dose, it took longer for all of the 
drug to diffuse into circulation and the duration of action of glatiramer was increased. 
2.3  Loading and characterisation of bevacizumab-NIPAAM hydrogel 
It is not possible to mix a large molecule such as a therapeutic protein efficiently with 
a preformed hydrogel. A strategy to address this ‘mixing problem’ is to form the gel 
while in the presence of the protein in solution. To prepare the loaded gels, 
bevacizumab (2.5 mg, 100 μL) was mixed with the monomer, initiator and 4, 8 and 
12 μL PEGDA. SEM images (bottom panel, Figure 3) indicate that freeze-dried 
bevacizumab-NIPAAM hydrogels have a similar morphology to the NIPAAM gels 
prepared without antibody (top panel, Figure 3). The bevacizumab loaded gel 
prepared using 8 μL PEGDA (beva-8μL gel) was easily injectable while also 
appearing to have an intact porous structure. 
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The beva-8μL PEGDA gel displayed a similar VPTT value (Figure 1A, 34.3 ± 
0.2°C) to the gel without bevacizumab that was prepared with the same amount of 
PEGDA. The SR of the beva-8μL PEGDA gel was slightly higher at 25°C than the 
unloaded NIPAAM gel (p<0.05), while at 37 and 48°C there was little difference in 
the SR between loaded and unloaded gels (Figure 1B). The WR of the beva-8μL 
PEGDA gel was the same as the unloaded NIPAAM gel (Figure 1C). It appears that 
the VPTT and the swelling properties of the NIPAAM gel do not significantly change 
in the presence of bevacizumab (2.5 mg) loading.  
 
Figure 3. Scanning electron microscopy (SEM) images of NIPAAM gels (40 μm scale). (Top 
panel) unloaded and (bottom panel) bevacizumab (2.5 mg) loaded NIPAAM hydrogels 
prepared PEGDA. Each sample was repeated in triplicate (n=3). 
A decreased SR was expected with increased crosslink density due to 
greater restriction of NIPAAM polymer chain mobility.[63] The hydrophilicity of PEGDA 
may result in a reduction of the NIPAAM hydrophobic interactions, which could also 
contribute to the reduction of SR with PEGDA incorporation.[64-66] However greater 
SR was observed for the more densely crosslinked hydrogel (e.g. 12 μL PEGDA; 
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unloaded gel (p<0.05) at 25°C; but not significantly different (p>0.05) at 37 and 48°C. 
As expected the decreased SR at 37 and 48°C was due to NIPAAM collapse and 
was not affected by the presence of bevacizumab.[33] Deswelling starts at the gel 
surface due to the free mobile nature of the surface and the diffusion of the 
crosslinked polymer network in water.[67] During gel collapse, some of entrapped 
protein can be released from the hydrogel.[63] The WR of beva-8μL PEGDA was 
similar to the unloaded gel (p>0.05). It was necessary to determine the hydrogel 
properties in the presence and absence of bevacizumab to ensure antibody loading 
did not adversely affect gel collapse properties. 
2.4  Bevacizumab loaded NIPAAM gel release profile 
Clearance profiles for the in situ loaded bevacizumab gels prepared were first 
determined using PBS in the PK-Eye (Figure 4A). The t1/2 of bevacizumab was 2.0 ± 
0.01, 3.7 ± 1.2  and 2.6 ± 0.03 days with the respective PEGDA amounts of 4, 8 and 
12 μL. Bimodal release profiles comprised of a first burst phase (60% of 
bevacizumab being cleared after 5 days) followed by a slower prolonged release 
phase are often observed with hydrogels.[34] Crosslink density appeared to have 
more impact on the second, slower phase of release with 74.2 ± 3.5, 87.6 ± 6.4 and 
95.8 ± 2.3% of the bevacizumab being released after a month with 4, 8 and 12 μL 
PEGDA respectively (Figure 4A). The in situ loaded beva-8μL PEGDA gel appeared 
to have a more prolonged release profile than was observed for either (i) the simple 
soaking or incubation of bevacizumab with a preformed gel NIPAAM hydrogel or (ii) 






Figure 4. Release profiles of bevacizumab (2.5 mg) loaded NIPAAM hydrogels released from 
either PBS or simulated vitreous in the PK-Eye at 37°C. (A) Bevacizumab and NIPAAM 
mixed in-situ then polymerised in the presence of different amounts of PEGDA crosslinker 
followed by release in PBS, (B) comparative release profiles in PBS of bevacizumab injection 
and bevacizumab NIPAAM loaded hydrogels prepared by hydrogel imbibition of a preformed 
gel and by in situ mixing during hydrogel formation crosslinked with PEGDA (8.0 L), (C) 
bevacizumab-in situ mixed NIPAAM hydrogel (8 μL PEGDA) compared to control (injection, 
no hydrogel) released from simulated vitreous and (D) washed versus unwashed 
bevacizumab from in situ mixed NIPAAM hydrogels released using PBS for release in the PK-
Eye. All data obtained by HPLC (280 nm) presented was done in triplicate (n=3) and 
presented as its mean and standard deviation (± STD). 
The incubation of bevacizumab with the preformed hydrogel resulted in 52.6 
± 7.3 and 92.0 ± 5.0% of the release of antibody after 2 and 7 days respectively. 
About 100.6 ± 3.4% of bevacizumab was released by day 17. These results were not 
surprising, as the gel tends to swell and completely expel the protein. The protein 
was not entangled within the hydrogel network. An outflow t1/2 of 1.9 ± 0.3 days was 
observed (Figure 4B) during the first rapid phase of the release. 































































































Although the use of PBS in the PK-Eye can estimate the clearance time for 
patients that have had a vitrectomy,[39] most patients will have their own vitreous. 
There was little difference in the release profiles when simulated vitreous was used 
with the beva-8μL gel or by simple injection of the antibody alone (Figure 4C). The 
viscosity of the simulated vitreous slowed the diffusion of bevacizumab once it was 
released from the gel compared to PBS. The rate of bevacizumab clearance during 
the first burst phase from the beva-8μL gel was dampened due to the reduced 
diffusion of the antibody from the viscous simulated vitreous within the PK-Eye. The 
difference observed using PBS and simulated vitreous in a relevant in vitro release 
model illustrate how it is possible to deconvolute characteristics of a release profile 
from a candidate drug delivery system.  
The viscosity and microstructure of the vitreous can vary between patients, 
and often the vitreous is less viscous in the elderly.[68] The t1/2 of bevacizumab in a 
victrectomised human eye from a single patient is 0.7 days,[69] so early knowledge in 
preclinical development about the difference in IVT release profiles that can range 
from being non-viscous to viscous has clinical implications. Many patients that 
require IVT injection of anti-VEGF therapeutic proteins have complex ocular 
conditions that may affect the vitreous properties or retinal permeation (e.g. torn 
inner limiting membrane) and may impact the clearance times of therapeutic 
proteins. For example, bevacizumab can have mean values in humans that vary from 
4.9 to 10 days.[58-61, 69] While a bevacizumab loaded gel would have more potential for 
patients that have a vitreous with reduced viscosity, there may be less benefit for the 
larger population of patients that would be expected to have a more intact vitreous. 
A post-polymerisation wash step as described elsewhere[34, 35] to remove 
leachable NIPAAM monomer and oligomeric species was examined using the beva-
8μL PEDGA gel. Upon polymerisation the gel was washed using several vials of 
PBS (4 ×, 5.0 mL each, 20 mL total) with gentle shaking/swirling for 5-10 mins for 
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each wash cycle. A total of 28% of the antibody was lost after the washing process. 
To compensate for the antibody losses due to washing, a larger amount of the 
washed beva-8μL PEDGAgel (125 μL) was evaluated in the PK-Eye using PBS and 
gave a similar release profile as observed for a 2.5 mg dose of the beva-8μL 
PEDGAgel (100 μL) that had not been washed (Figure 4D).  
2.5  Preparation of PEG10-Fabrani loaded NIPAAM gel 
Conjugation of poly(ethylene glycol) (PEG) to an antibody fragment was then 
examined because increased entanglement of the PEG molecules within the 
hydrogel could result in a longer diffusion time for the PEGylated protein from the 
hydrogel than an unmodified protein. Although double network gels are prepared by 
polymerising different macromolecules together, entanglement is important for the 
increased interaction between the two macromolecules.[70]   
The size of PEGylated proteins are dominated by the presence of the PEG 
that is conjugated to the protein.[71-74] PEG is a random coil polymer with an extended 
conformation in solution.[74] Proteins are often globular, more ordered and are smaller 
in size in solution than PEG, so protein entanglement would be expected to be less 
than what is possible for PEG. It was expected that if the NIPAAM monomer and 
PEGDA crosslinker were polymerised in the presence of PEG in solution, that better 
PEG entanglement would be achieved than the analogous polymerisation in the 
presence of the unmodified antibody. It was thought that PEG would form an 
interpenetrating polymer network (IPN)[75] with the PEGDA-NIPAAM network, which 
would result in slower diffusion of a PEGylated protein from the PEGDA crosslinked 
NIPAAM network than the unmodified protein (that is unable to become entangled in 
the hydrogel network). There would be better compatibility between the PEGDA 
crosslinked NIPAAM and PEG compared to the unmodified protein. Greater polymer-
polymer compatibility would be expected to contribute to better mixing of the 
PEGDA-NIPAAM and the Fab conjugated PEG chain.  
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PEGylating a full length antibody (PEG-IgG) may better entrap the antibody 
within a NIPAAM gel network. Although it is conceivable that a PEGylated antibody 
could have potential in the eye because the large solution structure of PEG would 
potentially further slow antibody diffusion in the vitreous to prolong clearance,[76-77] we 
decided to examine a PEGylated Fab (PEG-Fab) within the PEGDA-NIPAAM gel. 
Ranibizumab is a potent anti-VEGF drug that still maintains much of its binding 
affinity, especially at a low dissociation rate when PEGylated site-specifically.[78] It 
would be possible to more effectively load a gel with a higher mole fraction of PEG-
Fab than a PEG-IgG. PEGylated Fabs are used clinically, for example certolizumab 
pegol is a clinically used PEGylated Fab´ targeted to TNF- which is used 
systemically.[79]  
One desirable design criterion for any IVT drug delivery strategy is that once 
a therapeutic protein clears from the eye into the blood stream, that it then clears 
quickly from the body. PEG-Fab would be expected to clear more quickly from 
circulation than PEG-IgG. A PEGylated Fab has recently been studied after IVT 
administration to rabbits[80] and significant increases in t1/2 were observed with an 
increase in PEG molecular weight as compared to the unmodified protein. Clearance 
t1/2 times increase as the diffusivity of a molecule decreases within the vitreous.[76, 80] 
Larger molecules in solution diffuse more slowly with t1/2 being dependent on the 
hydrodynamic radius in solution.[77]  
We decided to used a 10 kDa PEG for Fab modification as it would be 
expected that once a PEG10-Fab clears from the eye that it then clear quickly from 
circulation. Ranibizumab (Fabrani) was selected for these studies because this Fab is 
clinically registered and we have studied the PEGylation of this Fab.[78] We utilised 
disulfide bridging PEGylation (Figure 5A-C) to site-specifically PEGylate Fabrani.[81-83] 
PEG10-Fabrani was obtained after pooling franctions from ion exchange 




Figure 5. (A) Preparation of PEG10-Fabrani from the conjugation of ranibizumab with PEG bis-
sulfone 1 derived from 10 kDa PEG precursor. (B) Disulfide bridging PEG conjugating 
reagents 1 undergo elimination of toluene sulfinic acid 2 to generate the PEG mono-sulfone 3 
which then undergo conjugation with a reduced native accessible disulfide in a protein. PEG 
bis-sulfone reagents 1 can be prepared using different PEG molecular weights and with 
different polymers.[82] The mono-sulfones 3 are latently crossed functionalised reagents 
capable of sequential and interactive addition-elimination reactions capable of bis-alkylation. 
(C) The mechanism for conjugation first shows the cysteine thiols are liberated by reduction 
(e.g. TCEP[84] or DTT) and then conjugation involves (i) a first thiol addition to the mono-
sulfone reagent 3, (ii) sulphinic acid 2 elimination to generate a second double bond in the 
reagent which is then followed by (iii) addition of the second thiol in from the original disulfide 
to give the bridged conjugate. (D) SDS-PAGE for the preparation of PEG10-Fabrani. Novex Bis-
Tris 4-12% gel stained with Coomassie blue (Lanes 1-5 and 8), barium iodide (Lanes 6-7) 
and silver stain (Lane 9). Lane 1: protein standard marker, Lane 2: Fabrani, Lane 3: Reduced 
Fabrani (5 mM DTT, before PD-10), Lane 4: Reduced Fabrani (after PD-10), Lanes 5 and 6: 
PEG10-Fabrani after conjugation with PEG10-bis sulfone 1 (before IEX), Lane 7: PEG10-bis 
sulfone 1 in pH 7.6, Lane 8: A fraction at ~16 mins shows a fraction of PEG10-Fabrani and 
Lane 9: Pooled and concentrated fractions of PEG10-Fabrani. Note that PEG migrates to about 
twice its molecular weight compared to marker proteins, so the band at 70 kDa is consistent 
with the formation of PEG10-Fabrani. 
A longer mixing time (3-4 hours) was conducted with PEG10-Fabrani, NIPAAM 
monomer, PEGDA, APS and TEMED to ensure gel formation occurs and to avoid 
precipitation. No gel was observed with a shorter mixing time (10 mins) as compared 
to bevacizumab loaded NIPAAM gels. The mixture was seen to ‘crash out’ of solution 




































































2.6 Release profile of PEG10-Fabrani loaded NIPAAM gel 
The release profile of the PEG10-Fabrani (1.0 mg in 100 μL) injection alone displayed a 
t1/2 of 9.7 ± 1.3 and 16.7 ± 1.9 days in PBS and simulated vitreous respectively 
(Figure 6A). Ranibizumab alone (0.5 mg, 50 μL) has previously been shown to have 
a t1/2 of 1.5 ± 0.6 and 8.0 ± 3.1 days in PBS and simulated vitreous respectively,[39] 
the latter being similar to human in vivo data (7.2[85] and 9.0[86] days). 
Pegaptanib (Macugen®) is a PEG-aptamer conjugated to a branched PEG 
(40 kDa total PEG molecular weight). It was the first approved anti-VEGF treatment 
for IVT injection.[87] The clinical dose of pegaptanib (0.3 mg) displays a t1/2 of 7-8 
days in humans.[88] Increasing the dose of pegaptanib by 10 times to 3.0 mg 
moderately increases the t1/2 to 10 (± 4). The t1/2 of 9.7 ± 1.3 days for PEG10-Fabrani is 
comparable to the human t1/2 of pegaptanib, so the PEG10-Fabrani loaded NIPAAM 
hydrogel was evaluated using PBS in the PK-Eye. The t1/2 of PEG10-Fabrani (2.0 mg, 
200 μL) from the NIPAAM gel was 15.1 ± 0.6 days which is significantly longer 
(p<0.05) than the t1/2 (9.9 ± 1.1 days) of an injection of PEG10-Fabrani of the same 
dose (Figure 6B). The amount of the PEG10-Fabrani cleared by day 33 was 75.5 ± 5.9 
and 92.3 ± 2.5% from the NIPAAM hydrogel and injection respectively.  
When considering the in situ loaded PEG10-Fabrani gel (Figure 6B), the 
clearance time was longer than for the release of PEG10-Fabrani  alone. However, the 
profile for the clearance of the in situ loaded PEG10-Fabrani  NIPAAM gel in PBS was 
the same as PEG10-Fabrani  alone from both PBS and simulated vitreous. There was 
no burst phase for the release of PEG10-Fabrani from the NIPAAM gel as there was for 
bevacizumab from the NIPAAM gel. In contrast to the analogous release of 
bevacizumab, release of PEG10-Fabrani from the NIPAAM gel was significantly slower 
than the release of PEG10-Fabrani without having been loaded into the gel, indicating 
that there was better mixing of the PEGylated Fab within the gel than there was for 




Figure 6. Cumulative release profiles of PEG10-Fabrani from the PK-Eye at 37°C; (A) 1.0 mg in 
PBS (pH 7.4) and simulated vitreous (SV) and (B) 2.0 mg mixed in situ into the hydrogel and 
injection without the hydrogel in PBS (pH 7.4). All data obtained by HPLC (280 nm) in 
triplicate (n=3) and presented as its mean and standard deviation (± STD). 
3.  Conclusion 
To promote good mixing that is required to load a protein into a hydrogel so that drug 
action can be prolonged in the back of the eye, thermoresponsive NIPAAM hydrogels 
were prepared in the presence of either bevacizumab or PEGylated ranibizumab. 
The in situ loaded bevacizumab-NIPAAM hydrogels displayed a bimodal and 
prolonged release profile compared to the release of bevacizumab from a preformed 
NIPAAM gel that had been loaded by prior incubation with a bevacizumab solution. 
The gel that was loaded by incubation had a similar release profile as bevacizumab, 
which had been administered in the absence of the hydrogel. Using simulated 
vitreous, the in situ loaded bevacizumab NIPAAM gel displayed a similar release 
profile as free bevacizumab. 
It was found that PEG10-Fabrani displayed a similar t1/2 to that of pegaptanib in 
humans using PBS in the PK-Eye. The in situ mixed NIPAAM loaded PEG10-Fabrani 
displayed a longer clearance t1/2 than free PEG10-Fabrani while following a similar 
release profile.  These results suggest that PEG entanglement within the PEGDA-
NIPAAM hydrogel results in better mixing of PEG10-Fabrani than it is possible for 
unmodified bevacizumab. Prolonging the release of a protein for IVT use from a 















































hydrogel requires that the protein and hydrogel are optimally mixed and evaluated in 
a realistic in vitro model of the eye based on aqueous outflow.  
4.  Experimental Section 
Materials 
Ranibizumab (Lucentis®, 10.0 mg/mL) and bevacizumab (Avastin® 25.0 mg/mL) from 
Genentech, South San Francisco, California were supplied from the leftover syringes 
and purchased from Moorfields Eye Hospital respectively. Protein integrity and 
stability were previously monitored by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), size exclusion chromatography (SEC) and surface 
plasmon resonance (SPR) with BIAcore. N-isopropylacrylamide (NIPAAM, 97%), 
N,N,N′,N′-tetramethylethylenediamine (TEMED, ~99%), ammonium persulfate (APS), 
poly(ethylene glycol) diacrylate (PEGDA, Mn: 700), DL-dithiothreitol (DTT), sodium 
triacetoxyborohydride (STAB), dimethyl sulfoxide (DMSO), InstantBlue™, 
poly(ethylene glycol) mono-amine (10 kDa), anhydrous toluene (99.8%), 
dichloromethane (DCM), 4-dimethyl amino pyridine (DMAP, 99+ %) and human 
vascular endothelial growth factor (hVEGF165) were purchased by Sigma-Aldrich 
(Gillingham, Dorset, UK). Ethylenediaminetetraacetic acid dihydrate (EDTA), acetone 
and sodium chloride were provided Fisher Scientific (Loughborough, Leicestershire, 
UK). Visking dialysis membrane tubing (MWCO of 12–14 kDa), agar and sodium 
hyaluronate (1.8 MDa) were obtained from Medicell International Ltd. (London, UK), 
Fluka Analytical (Gillingham, Dorset, UK) and Aston Chemicals (Aylesbury, UK) 
respectively. PD-10, Nap-10 and HiTrapTM SPHP columns were obtained from GE 
Healthcare (Amersham, UK). Viva 6 centrifugal concentrators (MWCO 10 kDa) were 
purchased from Generon (Berkshire, UK). Novex sharp pre-stained standard marker, 
NuPage® LDS sample buffer, 4-12% Bis-Tris polyacrylamide gels, 1.0 mm x 10 well 
and NuPage® MOPS running buffer were supplied from Life Technologies 
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(Northumberland, UK). Deuterated chloroform, CDCl3 (Cambridge Isotope 
Laboratories, Andover, UK) was used for nuclear magnetic resonance (NMR).  
Instrumentation 
A 16-channel Ismatec peristaltic pump (Michael Smith Engineers Ltd., Woking, 
Surrey, UK) was used to maintain fluid flow through the PK-Eye. High performance 
liquid chromatography (HPLC) was conducted using an Agilent 1200 series equipped 
with Chemstation software using a Zorbax GF-250 column (Agilent, Wokingham, 
Berkshire, UK). UV measurements were performed using a Hitachi U-2800A 
spectrometer using Quartz cuvettes (Starna Scientific Ltd) with a wavelength range 
of 200 nm to 800 nm and a Wallac Victor2 1420 plate reader. Scanning electron 
microscopy (SEM) was achieved using a QuantaTM 200F instrument (FEI 
Quanta200 FEGESEM, Eindhoven, The Netherlands). Different scanning calorimetry 
(DSC) experiments were performed on DSC Q2000 (TA instruments, Waters, LLC) 
with TA Instruments Universal Analysis 2000 software. A VIRTIS-Advantage freeze-
dryer was used for freeze-drying. SDS-PAGE was conducted using XcellSureLock 
gel electrophoresis tank (EI0001) and power supply (Life Technologies, 
Northumberland, UK). The IEX system had a UV detector (Jasco UV-1570) and 
HPLC pump (Jasco PU-980 Intelligent) with Azur software.  
NIPAAM gel preparation. 
Bevacizumab (0.5 or 1.0 mL of 25.0 mg/mL solution) was gently mixed with NIPAAM 
(40.0 mg, 3.5 × 10-4 moles) and APS (4.0 mg, 1.7 × 10-5 moles, 0.048 equiv.) for 10-
15 mins. PEGDA (Mn 700, δ: 1.12 g/mL, 25°C) was added in one of the following 
amounts: 4 (6.4 × 10-6 moles), 8 (1.3 × 10-5 moles) and 12 μL (1.9 × 10-5 moles) and 
the reaction mixtures were gently vortexed. TEMED (50 μL, δ: 0.775 g/mL, 20°C, 3.3 
× 10-4 moles) was then added and vortexed for 15-20 s. The mixture was stored in 
the fridge for 24 hours at 4°C. To wash, phosphate buffered saline (PBS, pH 7.4, 5.0 
mL) was added to the gelled product and gently mixed for 5-10 mins. This process 
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was repeated 4 times using a total of 20.0 mL of PBS. Unwashed gels were used 
directly after polymerisation. Protein loading of the gel was determined by HPLC (280 
nm).  
Preparation of bevacizumab loaded NIPAAM gels. 
NIPAAM (40 mg, 3.5 × 10-4 moles) and APS (4.0 mg, 1.7 × 10-5 moles, 0.048 equiv.) 
were dissolved in deionised water (1.0 mL) at RT (25°C). The contents were mixed 
for 10 mins (magnetic stir bar) until a clear solution was formed. Different PEGDA 
concentrations (Mn 700, δ: 1.12 g/mL, 25°C) were screened in the range of (0.018 to 
0.091 equiv. to NIPAAM). The amounts of PEGDA used in separate NIPAAM 
polymerisation reactions were 4 (6.4 × 10-6 moles), 8 (1.3 × 10-5 moles), 12 (1.9 × 
10-5 moles), 15 (2.4 × 10-5 moles) or 20 μL (3.2 × 10-5 moles) with increasing PEGDA 
used to increase the cross-link density of the NIPAAM gel. The reaction mixtures 
were vortexed for 10 min and then TEMED (δ: 0.775 g/mL, 20°C, 3.3 × 10-4 moles) 
was added. The mixture was again vortexed (~15-20 s) and then placed in a 
refrigerator (4°C, 24 h). 
The hydrogel was then freeze-dried prior to characterisation. All samples for 
freeze-drying were frozen in dry ice and then transferred to the freeze-drier at -40°C 
with a condenser temperature of -60°C. The vacuum pressure was maintained less 
than 200 mBar. The primary freeze-drying step was at -20°C for 48 hours. The 
temperature was increased to 20°C for 2 hours before opening the freeze-drier. 
Preparation of PEG10-Fabrani loaded NIPAAM hydrogels. 
The PEGylation reagent 1 used for conjugation was prepared as previously 
reported.[81-83] The conjugation buffer consisted of sodium phosphate monobasic 
(20.0 mM) and EDTA (10.0 mM) in distilled water (250.0 mL, Type I, 18.2 mΩ) and 
the pH was adjusting to 7.4. The prepared buffer was purged with argon before use. 
A solution of ranibizumab (Fabrani, 0.1 mL of 10.0 mg/mL) was prepared in 
conjugation buffer and it was reduced with DTT (5 mM, pH 7.4) for 30 mins at RT 
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(~25°C). The reduced Fabrani was buffer exchanged to pH 7.6 using a PD-10 column. 
The reduced Fabrani was found in the first 2.0 mL of the eluted buffer. PEG10 bis-
sulfone 1 was added to the reduced Fabrani at a PEG reagent:Fabrani ratio of 2:1 (pH 
7.6) and the conjugation mixture was incubated under an argon atmosphere for 5 
hours at RT.  
PEG10-Fabrani was then purified by ion exchange chromatography. Buffer A 
(sodium acetate trihydrate, 50.0 mM) and buffer B (sodium acetate trihydrate, 50 mM 
and sodium chloride 500 mM) were prepared in distilled water (500.0 mL, Type I, 
18.2 mΩ resistance) and adjusted to pH 4.0. The buffers were filtered prior to 
connecting them to the HPLC with a 0.45 μm with a Millipore filter flask fitted with 
cellulose nitrate membrane. A Nap-10 column was washed and equilibrated with 
buffer A. The conjugate (1.0 mL) was buffer exchanged with buffer A (1.5 mL) to give 
the protein a charge that would allow binding to the column. The flow-through was 
collected and loaded to the SPHP column. A linear gradient was used by first eluting 
100% buffer A for 10 minutes, then gradually eluting 100% buffer B over a 30 minute 
period (total run time: 40 mins). The column effluent was monitored by UV (280 nm). 
Fractions (~1.0 mL) were collected and analysed by SDS-PAGE to isolate PEG10-
Fabrani. The PEG10-Fabrani fractions were pooled and concentrated with viva-spin 
(MWCO 10 kDa) to ~1.0 mL and the UV absorbance was recorded at 280 nm. The 
conjugate was then stabilised by the addition of sodium triacetoxyborohydride 
(STAB, 50 mM) dissolved in DMSO at 4°C for 1.5 hours. The crude reaction mixture 
was buffer exchanged with a PD-10 column into 50 mM PBS, pH 7.4.  
PEG10-Fabrani (0.5-2.0 mg) was gently mixed (magnetic stir bar) with NIPAAM 
(40 mg, 3.5 × 10-4 moles) and APS (4.0 mg, 1.7 × 10-5 moles) for 3-4 hours (RT). 
PEGDA i.e. 8 μL (δ: 1.12 g/mL, 25°C, 1.3 × 10-5 moles) was then added and 
vortexed. TEMED (50 μL, δ: 0.775 g/mL, 20°C, 3.3 × 10-4 moles) was added and 
vortexed. The mixture was incubated in the fridge for 24 hours at 4°C. 
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Determination of volume phase transition temperature (VPTT) 
The VPTT was measured using differential scanning calorimetry (DSC) at 2°C/min 
from 20 to 50°C. Calibration with Indium (Tm = 156.6, ∆Hf =28.71 J/g) was 
performed according to the manufacturer instructions. Nitrogen was used as purge 
gas with a flow rate of 40.0 mL/min for all the experiments. The onset temperature of 
the DSC endothermic peak was considered as the VPTT.  
Determination of swelling ratio (SR) and water retention (WR) 
Freeze dried hydrogel samples were weighed (Wd) and rehydrated in deionised 
water for approximately 48 hours to ensure full hydration of the hydrogel. Hydrogels 
were allowed to reach equilibrium swelling at three different temperatures (25, 37 
and 48°C). The fully hydrated samples were then removed and weighed to measure 
their weight at equilibrium with water (We). Excess water was removed from the 
sample by tapping the surface carefully with filter paper before reweighing. A 
gravimetric method was used to measure the swelling ratio (Q) of the prepared 






Water retention percentage (WR%) was measured using the gravimetric 
method at 50°C. Freeze-dried hydrogel samples were weighed (Wd) and were fully 
hydrated at RT (~25°C) in deionised water (10.0 mL) for 48 hours. The fully hydrated 
gels were weighed (We) and quickly transferred to pre-heated water at 50°C in an 
incubator. The samples were weighed at pre-determined time intervals. The samples 
were removed from the incubator, quickly weighed (Wt) and returned back to the 
incubator before each measurement. WR% was calculated for each time point 
according to Equation 2. 






Scanning electron microscopy (SEM). 
Samples were cut and adhered onto aluminium SEM stubs using carbon-coated 
double-sided tape prior to SEM analysis. The samples were then sputter coated with 
gold prior to imaging to make them electrically conductive.  
In vitro release studies using the PK-Eye. 
The in vitro PK-Eye is a two-compartment model comprised of anterior (0.2 mL) and 
posterior (4.2 mL) cavities separated with a washer and Visking membrane (MWCO 
12-14 kDa). For PEG10-Fabrani studies, a solution of Tween 20 (30%) in distilled water 
was first prepared. Freshly cut Visking membranes were incubated in the Tween 20 
solution for ~12 hours at 37°C. The membranes were then rinsed gently with distilled 
water and the membranes were fitted with the washer and integrated within the 
model. The control in this experiment was the membrane not treated with Tween 20.  
The inlet port of the PK-Eye was connected to a peristaltic pump with a flow 
of 2.0 μL/min. One outlet port is present in the anterior cavity for continuous 
sampling. An injection port is present in both cavities (diameter: 2.0-3.0 mm) to allow 
formulation administration into the model. Prior to each experiment, the PK-Eye was 
unscrewed and a fresh Visking membrane was incorporated. The models were 
assembled and the anterior cavity was filled with PBS, pH 7.4, whereas the posterior 
cavity was filled with simulated vitreous or PBS. The models were immersed in a 
preheated oil bath adjusted to 37°C for 2 hours to equilibrate prior to the release 
studies. Temperature was maintained using a probe connected to the hotplate 
heater. 
To prepare simulated vitreous with a dynamic viscosity of 0.6 Pa.s,[39] which is 
similar to the human vitreous viscosity (~0.5 Pa.s).[89] Agar (0.4 g) and hyaluronic 
acid (HA) (0.5 g) were separately mixed in 100 mL of boiled water.[90] The agar 
solution was boiled to completely solubilise the agar. After boiling, the hot agar 
solution was mixed with HA and stirred to give a homogenous mixture to which a few 
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drops of 0.02% sodium azide were added. The solution was left to cool for 24 hours 
at RT to form a gel-like consistency. 
The following formulations were injected to the posterior cavity of the PK-Eye 
via a 23 G needle: (i) injection form of bevacizumab (Avastin®, 25 mg/mL), 1.25 (50 
μL), 2.5 (100 μL) and 5.0 mg (200 μL); (ii) bevacizumab (2.5 mg, 100 μL) loaded 
NIPAAM gels with PEGDA (4, 8 and 12 μL); (iii) Injection form of PEG10-Fabrani, 0.6 
(50 μL), 1.0, (100 μL) and 2.0 mg (200 μL) and (iv) PEG10-Fabrani (2.0 mg, 200 μL) 
loaded NIPAAM gels with PEGDA (8 μL). Samples were collected from the anterior 
cavity and quantified by HPLC (280 nm). 
Protein quantification by high performance liquid chromatography (HPLC) 
Protein concentration was determined by HPLC with an Agilent Zorbax GF-250 
column fitted with a guard column. The mobile phase was PBS, pH 7.4 previously 
purged with argon and sonicated. A wavelength of 280 nm was adjusted with a run 
time of 12 minutes. The injection volume was 100 μL with a flow rate of 1.0 mL/min. 
A calibration curve was made with a 0.0019-1.0 mg/mL of protein in PBS, pH 7.4. 
Bevacizumab and ranibizumab had a reported R2 value of 0.996 and 0.987 
respectively. A retention time of approximately 2.3 mins was observed.  
Data analysis  
All results are presented as the mean (n=3) and standard deviation (± STD), and 
data were plotted using OriginPro 9.1 (software, Origin lab cooperation, USA). Half-
life (t1/2) values were calculated according to the best fitting model in OriginPro. First-
order kinetic rate constants (k) were derived from the mono-exponential curve and 
t1/2 was calculated using the equation: 0.693/k. The rate constants (k) of zero-order 
release profiles were calculated as concentration-time and t1/2 was calculated from 
initial concentration [A] using [A]/2k. The analysis of variance (one-way and repeated 
measure ANOVA) with Tukey’s post hoc test was conducted to evaluate differences 
between the experimental data (mean values) using OriginPro 9.1 and IBM SPSS 
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statistics 23. Probability values less than 0.05 (p<0.05) were considered as indicative 
of statistically significant differences. 
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